Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

CONCLUSION: These findings suggest a potential role of Trop-2 expression as a biomarker of resistance to neoadjuvant chemotherapy plus dual HER2 blockade and may become a strategic target for future combinations in HER2-positive EBC patients.PMID:38456970 | DOI:10.1007/s10549-024-07292-z

Source: Cell Research - March 8, 2024 Category: Cytology Authors: Mar ía Gion Juan Jos é García-Mosquera Jos é Manuel Pérez-García Vicente Peg Manuel Ruiz-Borrego Agostina Stradella Bego ña Bermejo Jos é Antonio Guerrero Laura L ópez-Montero Mario Mancino Jos é Rodríguez-Morató Gabriele Antonarelli Miguel Sa Source Type: research